204 related articles for article (PubMed ID: 37770968)
1. B7H3-targeting chimeric antigen receptor modification enhances antitumor effect of Vγ9Vδ2 T cells in glioblastoma.
Wang Y; Ji N; Zhang Y; Chu J; Pan C; Zhang P; Ma W; Zhang X; Xi JJ; Chen M; Zhang Y; Zhang L; Sun T
J Transl Med; 2023 Sep; 21(1):672. PubMed ID: 37770968
[TBL] [Abstract][Full Text] [Related]
2. BTN2A1, an immune checkpoint targeting Vγ9Vδ2 T cell cytotoxicity against malignant cells.
Cano CE; Pasero C; De Gassart A; Kerneur C; Gabriac M; Fullana M; Granarolo E; Hoet R; Scotet E; Rafia C; Herrmann T; Imbert C; Gorvel L; Vey N; Briantais A; le Floch AC; Olive D
Cell Rep; 2021 Jul; 36(2):109359. PubMed ID: 34260935
[TBL] [Abstract][Full Text] [Related]
3. Butyrophilin-2A1 Directly Binds Germline-Encoded Regions of the Vγ9Vδ2 TCR and Is Essential for Phosphoantigen Sensing.
Karunakaran MM; Willcox CR; Salim M; Paletta D; Fichtner AS; Noll A; Starick L; Nöhren A; Begley CR; Berwick KA; Chaleil RAG; Pitard V; Déchanet-Merville J; Bates PA; Kimmel B; Knowles TJ; Kunzmann V; Walter L; Jeeves M; Mohammed F; Willcox BE; Herrmann T
Immunity; 2020 Mar; 52(3):487-498.e6. PubMed ID: 32155411
[TBL] [Abstract][Full Text] [Related]
4. Self-activation of Vγ9Vδ2 T cells by exogenous phosphoantigens involves TCR and butyrophilins.
Laplagne C; Ligat L; Foote J; Lopez F; Fournié JJ; Laurent C; Valitutti S; Poupot M
Cell Mol Immunol; 2021 Aug; 18(8):1861-1870. PubMed ID: 34183807
[TBL] [Abstract][Full Text] [Related]
5. Cutting Edge: Bispecific γδ T Cell Engager Containing Heterodimeric BTN2A1 and BTN3A1 Promotes Targeted Activation of Vγ9Vδ2
Lai AY; Patel A; Brewer F; Evans K; Johannes K; González LE; Yoo KJ; Fromm G; Wilson K; Schreiber TH; de Silva S
J Immunol; 2022 Oct; 209(8):1475-1480. PubMed ID: 36096643
[TBL] [Abstract][Full Text] [Related]
6. [Butyrophilin 3A1 (BTN3A1) enhances activation and proliferation of human peripheral blood Vγ9Vδ2 T cells induced by MTB-HAg].
Tang J; Sun J; Zha C; Chang J; Hu K; Fang Q; Chen Y; Chen J; Li B
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2020 Aug; 36(8):680-686. PubMed ID: 32958123
[TBL] [Abstract][Full Text] [Related]
7. Phosphoantigens glue butyrophilin 3A1 and 2A1 to activate Vγ9Vδ2 T cells.
Yuan L; Ma X; Yang Y; Qu Y; Li X; Zhu X; Ma W; Duan J; Xue J; Yang H; Huang JW; Yi S; Zhang M; Cai N; Zhang L; Ding Q; Lai K; Liu C; Zhang L; Liu X; Yao Y; Zhou S; Li X; Shen P; Chang Q; Malwal SR; He Y; Li W; Chen C; Chen CC; Oldfield E; Guo RT; Zhang Y
Nature; 2023 Sep; 621(7980):840-848. PubMed ID: 37674084
[TBL] [Abstract][Full Text] [Related]
8. Mutations to the BTN2A1 Linker Region Impact Its Homodimerization and Its Cytoplasmic Interaction with Phospho-Antigen-Bound BTN3A1.
Nguyen K; Jin Y; Howell M; Hsiao CC; Wiemer AJ; Vinogradova O
J Immunol; 2023 Jul; 211(1):23-33. PubMed ID: 37171180
[TBL] [Abstract][Full Text] [Related]
9. Up-regulation of BTN3A1 on CD14
Zhou J; Zhang J; Tao L; Peng K; Zhang Q; Yan K; Luan J; Pan J; Su X; Sun J; Zhang Z; Shen L
Proc Natl Acad Sci U S A; 2022 Nov; 119(44):e2117523119. PubMed ID: 36288286
[TBL] [Abstract][Full Text] [Related]
10. B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres.
Nehama D; Di Ianni N; Musio S; Du H; Patané M; Pollo B; Finocchiaro G; Park JJH; Dunn DE; Edwards DS; Damrauer JS; Hudson H; Floyd SR; Ferrone S; Savoldo B; Pellegatta S; Dotti G
EBioMedicine; 2019 Sep; 47():33-43. PubMed ID: 31466914
[TBL] [Abstract][Full Text] [Related]
11. Ligand-induced interactions between butyrophilin 2A1 and 3A1 internal domains in the HMBPP receptor complex.
Hsiao CC; Nguyen K; Jin Y; Vinogradova O; Wiemer AJ
Cell Chem Biol; 2022 Jun; 29(6):985-995.e5. PubMed ID: 35081362
[TBL] [Abstract][Full Text] [Related]
12. ABCA1, apoA-I, and BTN3A1: A Legitimate Ménage à Trois in Dendritic Cells.
Riganti C; Castella B; Massaia M
Front Immunol; 2018; 9():1246. PubMed ID: 29937767
[TBL] [Abstract][Full Text] [Related]
13. Phosphoantigen-induced conformational change of butyrophilin 3A1 (BTN3A1) and its implication on Vγ9Vδ2 T cell activation.
Gu S; Sachleben JR; Boughter CT; Nawrocka WI; Borowska MT; Tarrasch JT; Skiniotis G; Roux B; Adams EJ
Proc Natl Acad Sci U S A; 2017 Aug; 114(35):E7311-E7320. PubMed ID: 28807997
[TBL] [Abstract][Full Text] [Related]
14. Incorporating IL7 receptor alpha signaling in the endodomain of B7H3-targeting chimeric antigen receptor T cells mediates antitumor activity in glioblastoma.
Sakunrangsit N; Khuisangeam N; Inthanachai T; Yodsurang V; Taechawattananant P; Suppipat K; Tawinwung S
Cancer Immunol Immunother; 2024 Apr; 73(6):98. PubMed ID: 38619641
[TBL] [Abstract][Full Text] [Related]
15. Listeria monocytogenes-infected human monocytic derived dendritic cells activate Vγ9Vδ2 T cells independently of HMBPP production.
Alice AF; Kramer G; Bambina S; Bahjat KS; Gough MJ; Crittenden MR
Sci Rep; 2021 Aug; 11(1):16347. PubMed ID: 34381163
[TBL] [Abstract][Full Text] [Related]
16. Phosphoantigen sensing combines TCR-dependent recognition of the BTN3A IgV domain and germline interaction with BTN2A1.
Willcox CR; Salim M; Begley CR; Karunakaran MM; Easton EJ; von Klopotek C; Berwick KA; Herrmann T; Mohammed F; Jeeves M; Willcox BE
Cell Rep; 2023 Apr; 42(4):112321. PubMed ID: 36995939
[TBL] [Abstract][Full Text] [Related]
17. Targeting of the alpha
Cobb DA; de Rossi J; Liu L; An E; Lee DW
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35210306
[TBL] [Abstract][Full Text] [Related]
18. Vγ9Vδ2 T cell activation by strongly agonistic nucleotidic phosphoantigens.
Moulin M; Alguacil J; Gu S; Mehtougui A; Adams EJ; Peyrottes S; Champagne E
Cell Mol Life Sci; 2017 Dec; 74(23):4353-4367. PubMed ID: 28669030
[TBL] [Abstract][Full Text] [Related]
19. Large-scale expansion of Vγ9Vδ2 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor-modified effector cells.
Xiao L; Chen C; Li Z; Zhu S; Tay JC; Zhang X; Zha S; Zeng J; Tan WK; Liu X; Chng WJ; Wang S
Cytotherapy; 2018 Mar; 20(3):420-435. PubMed ID: 29402645
[TBL] [Abstract][Full Text] [Related]
20. Unsynchronized butyrophilin molecules dictate cancer cell evasion of Vγ9Vδ2 T-cell killing.
Wu Z; Lamao Q; Gu M; Jin X; Liu Y; Tian F; Yu Y; Yuan P; Gao S; Fulford TS; Uldrich AP; Wong CC; Wei W
Cell Mol Immunol; 2024 Apr; 21(4):362-373. PubMed ID: 38374404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
